Nuvo Group introduced that it has obtained 510(ok) clearance from the FDA to market INVU, a wearable machine that remotely displays fetal and maternal coronary heart charges.

Fetal and maternal coronary heart charges are necessary measurements late
in being pregnant, and an elevated fetal coronary heart price will be one of many first indicators
of fetal misery. Presently, acquiring these important indicators requires common workplace
visits and use of an digital fetal monitor. INVU permits sufferers and
physicians to observe these knowledge factors remotely with comfort and accuracy.

The machine will probably be prescription-only and is supposed to be used within the third trimester of being pregnant. The healthcare supplier will schedule distant monitoring periods, throughout which the affected person wears the INVU sensor band to gather coronary heart price knowledge. Measurements are accessible by a smartphone app and are additionally uploaded to a clinician dashboard for the healthcare supplier.

The Tel Aviv-based firm
touts that its distant monitoring platform is particularly related through the
present COVID-19 pandemic. Dr. Joshua Copel, chair of Nuvo’s medical
advisory board and professor of obstetrics and gynecology at Yale College of
Medication, stated in an announcement: “Providing pregnant ladies new and extra handy
methods to attach with OB suppliers can enhance entry to specialty care,
improve affected person expertise in a manner that’s secure, cost-effective and threat
applicable, and—importantly through the present COVID-19 pandemic—reduce
pointless publicity.”

Product web page: INVU

By way of: Nuvo Group